A detailed history of First Horizon Advisors, Inc. transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 507 shares of AGIO stock, worth $29,963. This represents 0.0% of its overall portfolio holdings.

Number of Shares
507
Previous 507 -0.0%
Holding current value
$29,963
Previous $21,000 4.76%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$27.55 - $48.83 $2,231 - $3,955
-81 Reduced 13.78%
507 $21,000
Q1 2024

Apr 26, 2024

BUY
$21.32 - $34.81 $3,453 - $5,639
162 Added 38.03%
588 $17,000
Q4 2023

Feb 06, 2024

BUY
$19.97 - $24.53 $399 - $490
20 Added 4.93%
426 $9,000
Q3 2023

Oct 27, 2023

BUY
$24.36 - $28.18 $755 - $873
31 Added 8.27%
406 $10,000
Q2 2023

Aug 03, 2023

BUY
$21.38 - $29.19 $1,154 - $1,576
54 Added 16.82%
375 $10,000
Q1 2023

May 15, 2023

SELL
$21.74 - $30.93 $521 - $742
-24 Reduced 6.96%
321 $7,000
Q4 2022

Feb 10, 2023

BUY
$24.81 - $31.52 $669 - $851
27 Added 8.49%
345 $9,000
Q3 2022

Nov 09, 2022

BUY
$19.51 - $34.14 $819 - $1,433
42 Added 15.22%
318 $9,000
Q2 2022

Aug 02, 2022

BUY
$17.06 - $31.42 $1,859 - $3,424
109 Added 65.27%
276 $6,000
Q1 2022

May 10, 2022

BUY
$26.68 - $34.81 $3,548 - $4,629
133 Added 391.18%
167 $5,000
Q4 2021

Feb 09, 2022

BUY
$29.58 - $49.78 $650 - $1,095
22 Added 183.33%
34 $1,000
Q3 2021

Nov 15, 2021

SELL
$41.92 - $58.18 $25,696 - $35,664
-613 Reduced 98.08%
12 $0
Q3 2021

Nov 09, 2021

BUY
$41.92 - $58.18 $26,200 - $36,362
625 New
625 $28,000

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $3.24B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.